Alx oncology announces participation in the jefferies global healthcare conference

South san francisco, calif., may 29, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today announced that management will participate in the jefferies global healthcare conference. details are as follows:
ALXO Ratings Summary
ALXO Quant Ranking